Next-gen mpox treatments: FDA calls for diverse, randomized controlled trials
For companies looking to develop the next mpox (formerly known as monkeypox) antivirals, the FDA came out with new draft guidance yesterday spelling out the details of what such development programs should include.
One of the major points in the draft is the FDA is calling for any new mpox treatments to run randomized controlled trials with wide racial and ethnic diversity and those with HIV, as mpox disproportionately affects these populations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.